Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Project Name | Project Stage | Molecule Type | Host Species | Therapeutic Area | Indications |
| CXCR4 mAb - 01 | Lead | Hematological Malignancy,AutoImmunity | Blood tumor,Solid tumor |
| Project Name | Modality | Therapeutic Area | Indications | Stage | Right Available |
| DHODH inhibitor | Small molecule | Alimentary disease | inflammatory bowel disease | IND | Global |
| 5-HT1F agonist | Small molecule | Neurological disease | Migraine | Phase I | Global |
| Capsid Assembly Inhibitors for HBV | Small molecule | Infectious and parasitic diseases | HBV | Phase III | Global (except China) |
| PI3Kδ inhibitor | Small molecule | Oncology/Cancer | Hematologic malignancies | Phase I | Global |
| Capsid Assembly Inhibitors for HBV | Small molecule | Infectious and parasitic diseases | HBV | Phase I | Global (except China) |
| RET high selective inhibitor | Small molecule | Oncology/Cancer | NSCLC,Medullary thyroid cancer,Thyroid cancer | Phase I | Global |
| A SSRI & Partial 5-HT1A Agonist | Small molecule | Neurological disease | Depression | Phase III | Global |
| sGC stimulator | Small molecule | Cardiovascular | PAH,CTEPH,HFrEF,CKD | Phase I | Global |
| XO/URAT1 Dual target inhibitors for HUA | Small molecule | Metabolic disease | Hyperuricimia | Phase I | Global |
| FXR Agonist | Small molecule | Metabolic disease | NASH | Phase II | Global |
| SGLT2 inhibitor | Small molecule | Metabolic disease | Diabetes | Phase III | Global (except China) |
| FXR Agonist | Small molecule | Metabolic disease | Diabetic kidney disease | Phase I | Global |
| ACC inhibitor treating NASH | Small molecule | Metabolic disease | NASH | IND | Global |
| Oxazolidone (new compounds) antibiotics | Small molecule | Infectious and parasitic diseases | gram-positive bacterial infections | IND | Global |
| NF-kB inhibitor (Novel small molecule drug) for cancer cachexia | Small molecule | Oncology/Cancer | Cancer cachexia | PCC | Global |
| HIF-PHs inhibitor for CKD and Renal anemia | Small molecule | Blood and Clotting disease | CKD,Renal anemia | Phase I | Global (except China) |
| PI3K/mTOR dual inhibitor | Small molecule | Oncology/Cancer,Respiratory disease | IPF,solid tumor | Phase I | Global (except China) |
| EED inhibitor | Small molecule | Oncology/Cancer | Solid tumor,Hematological malignancy | IND | Global |
| Viscous Gel Temozolomide | Small molecule | Oncology/Cancer,Neurological disease | Glioblastoma | Phase I | Global except CIA |
| Modified vilazodone | Small molecule | Neurological disease | Major Depressive Disorder | BE | Global |
| PI3Kδ inhibitor | Small molecule | Oncology/Cancer | Advanced solid tumors | Phase I | Global |
| PARP inhibitor | Small molecule | Oncology/Cancer | Advanced malignant solid tumors | Phase I | Global |
| DHODH inhibitor | Small molecule | Oncology/Cancer | Small cell lung cancer | IND | Global |
| FXIα inhibitor | Small molecule | Blood and Clotting disease | Arterial thrombosis,Phlebothrombosis,Thrombosis | Phase I | Global (except China) |
| Liver-Targeting THR-β Agonist | Small molecule | Metabolic disease | Nonalcoholic Steatohepatitis (NASH) | Phase I | Global |
| PI3Kδ inhibitor | Small molecule | Oncology/Cancer | Solid tumor,Hematological malignancies | PCC | Global |
2% serum diluted by Dilution Buffer : Biotinylated SARS-CoV-2 S protein RBD was put into, the background value is 2.383 and 2.148; 2% serum diluted by DB-02 : Biotinylated SARS-CoV-2 S protein RBD was put into, the background value is 0.262 and 0.263. In the existence of DB-02, the serum background values significantly decreased. Note: Dilution Buffer is Wash Buffer with 0.5% (w/v) bovine serum albumin (BSA), 50 mL.
This web search service is supported by Google Inc.
A-Z
